Which has better valuation & earnings, LXEO or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A

Is LXEO or ALDX more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Aldeyra Therapeutics N/A -57.34% -36.33%

Does the media prefer LXEO or ALDX?

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Lexeo Therapeutics and 3 mentions for Aldeyra Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.09 beat Aldeyra Therapeutics' score of 0.96 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALDX or XFOR?

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for X4 Pharmaceuticals and 3 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat X4 Pharmaceuticals' score of 0.42 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, DMAC or ALDX?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A

Is DMAC or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.15% -69.23% Aldeyra Therapeutics N/A -57.34% -36.33%

Does the media favor DMAC or ALDX?

In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for DiaMedica Therapeutics and 3 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat DiaMedica Therapeutics' score of 0.92 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FENC or ALDX?

In the previous week, Adherex Technologies had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Adherex Technologies and 3 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat Adherex Technologies' score of 0.45 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALDX or UPB?

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 2 mentions for Upstream Bio. Aldeyra Therapeutics' average media sentiment score of 0.96 beat Upstream Bio's score of 0.90 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aldeyra Therapeutics (ALDX) Competitors

$1.61 +0.06 (+4.00%)

As of 09:30 AM Eastern

Compare

ALDX vs. LXEO, XFOR, DMAC, FENC, and UPB

Should you buy Aldeyra Therapeutics stock or one of its competitors? MarketBeat compares Aldeyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aldeyra Therapeutics include Lexeo Therapeutics (LXEO), X4 Pharmaceuticals (XFOR), DiaMedica Therapeutics (DMAC), Adherex Technologies (FENC), and Upstream Bio (UPB).

How does Aldeyra Therapeutics compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Lexeo Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Lexeo Therapeutics and 3 mentions for Aldeyra Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.09 beat Aldeyra Therapeutics' score of 0.96 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexeo Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 316.57%. Aldeyra Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 241.19%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lexeo Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexeo Therapeutics' return on equity of -47.48% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Summary

Lexeo Therapeutics beats Aldeyra Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to X4 Pharmaceuticals?

Aldeyra Therapeutics (NASDAQ:ALDX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Aldeyra Therapeutics has higher earnings, but lower revenue than X4 Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
X4 Pharmaceuticals	$35.11M	11.44	-$79.20M	-$4.54	N/A

Aldeyra Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aldeyra Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 241.19%. X4 Pharmaceuticals has a consensus target price of $9.70, indicating a potential upside of 127.70%. Given Aldeyra Therapeutics' higher probable upside, research analysts clearly believe Aldeyra Therapeutics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for X4 Pharmaceuticals and 3 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat X4 Pharmaceuticals' score of 0.42 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Aldeyra Therapeutics' return on equity of -57.34% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

Summary

Aldeyra Therapeutics beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for DiaMedica Therapeutics and 3 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat DiaMedica Therapeutics' score of 0.92 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Aldeyra Therapeutics' return on equity of -57.34% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DiaMedica Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

DiaMedica Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 83.15%. Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 241.19%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aldeyra Therapeutics beats DiaMedica Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adherex Technologies has higher revenue and earnings than Aldeyra Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	7.93	-$9.74M	-$0.29	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

In the previous week, Adherex Technologies had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Adherex Technologies and 3 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat Adherex Technologies' score of 0.45 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adherex Technologies has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Adherex Technologies currently has a consensus price target of $15.40, suggesting a potential upside of 52.31%. Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 241.19%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Summary

Adherex Technologies beats Aldeyra Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Upstream Bio?

Aldeyra Therapeutics (NASDAQ:ALDX) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Aldeyra Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Aldeyra Therapeutics has higher earnings, but lower revenue than Upstream Bio. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Upstream Bio	$2.85M	129.14	-$143.44M	-$2.91	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 241.19%. Upstream Bio has a consensus price target of $33.17, suggesting a potential upside of 390.41%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts plainly believe Upstream Bio is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 2 mentions for Upstream Bio. Aldeyra Therapeutics' average media sentiment score of 0.96 beat Upstream Bio's score of 0.90 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Upstream Bio beats Aldeyra Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$99.23M	$11.51B	$6.84B	$12.77B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	-3.58	791.62	279.15	25.53
Price / Sales	N/A	735.80	590.96	92.31
Price / Cash	N/A	71.54	72.11	49.39
Price / Book	2.18	10.85	13.02	6.11
Net Income	-$33.85M	$2.81B	$3.48B	$347.58M
7 Day Performance	0.12%	2.73%	3.40%	4.91%
1 Month Performance	-28.99%	-3.09%	-2.80%	-2.06%
1 Year Performance	-68.76%	191.01%	73.17%	21.03%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	3.6282 of 5 stars	$1.61 +4.0%	$5.50 +241.2%	-69.5%	$99.23M	N/A	N/A	10	News Coverage Positive News Upcoming Earnings
LXEO Lexeo Therapeutics	2.2775 of 5 stars	$4.47 -4.1%	$18.75 +319.5%	-7.5%	$365.91M	N/A	N/A	58	Positive News
XFOR X4 Pharmaceuticals	2.4406 of 5 stars	$3.94 +2.3%	$9.70 +146.2%	+171.5%	$363.13M	$35.11M	N/A	80	Upcoming Earnings
DMAC DiaMedica Therapeutics	1.7309 of 5 stars	$6.74 flat	$12.00 +78.0%	+50.5%	$362.90M	N/A	N/A	20	News Coverage Positive News Upcoming Earnings
FENC Adherex Technologies	3.9241 of 5 stars	$10.21 +2.2%	$15.40 +50.8%	+21.5%	$349.99M	$44.64M	N/A	10	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. LXEO, XFOR, DMAC, FENC, and UPB

How does Aldeyra Therapeutics compare to Lexeo Therapeutics?

Summary

How does Aldeyra Therapeutics compare to X4 Pharmaceuticals?

Summary

How does Aldeyra Therapeutics compare to DiaMedica Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Adherex Technologies?

Summary

How does Aldeyra Therapeutics compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. LXEO, XFOR, DMAC, FENC, and UPB

How does Aldeyra Therapeutics compare to Lexeo Therapeutics?

Which has better valuation & earnings, LXEO or ALDX?

Which has more volatility & risk, LXEO or ALDX?

Do insiders and institutionals hold more shares of LXEO or ALDX?

Does the media prefer LXEO or ALDX?

Do analysts recommend LXEO or ALDX?

Is LXEO or ALDX more profitable?

Summary

How does Aldeyra Therapeutics compare to X4 Pharmaceuticals?

Which has higher earnings and valuation, ALDX or XFOR?

Which has more volatility & risk, ALDX or XFOR?

Do insiders and institutionals believe in ALDX or XFOR?

Do analysts recommend ALDX or XFOR?

Does the media refer more to ALDX or XFOR?

Is ALDX or XFOR more profitable?

Summary

How does Aldeyra Therapeutics compare to DiaMedica Therapeutics?

Does the media favor DMAC or ALDX?

Which has better valuation & earnings, DMAC or ALDX?

Is DMAC or ALDX more profitable?

Do insiders and institutionals hold more shares of DMAC or ALDX?

Which has more risk and volatility, DMAC or ALDX?

Do analysts rate DMAC or ALDX?

Summary

How does Aldeyra Therapeutics compare to Adherex Technologies?

Do institutionals and insiders have more ownership in FENC or ALDX?

Which has higher valuation and earnings, FENC or ALDX?

Does the media refer more to FENC or ALDX?

Which has more volatility & risk, FENC or ALDX?

Do analysts prefer FENC or ALDX?

Is FENC or ALDX more profitable?

Summary

How does Aldeyra Therapeutics compare to Upstream Bio?

Which has more volatility and risk, ALDX or UPB?

Which has preferable valuation and earnings, ALDX or UPB?

Is ALDX or UPB more profitable?

Do analysts prefer ALDX or UPB?

Does the media favor ALDX or UPB?

Do institutionals & insiders have more ownership in ALDX or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools